Elite Laboratories, Inc.
Records under this name other than the patents Elite Laboratories, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 8 of 8 · Back to Elite Laboratories, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,425,933 | Abuse-resistant oral dosage forms and method of use thereof Term ended Term ended Mar 3, 2025 · From the USPTO record | Term ended | Term ended Mar 3, 2025 | From the USPTO record |
| US 8,182,836 | Abuse-resistant oral dosage forms and method of use thereof Term ended Term ended Mar 16, 2024 · From the USPTO record | Term ended | Term ended Mar 16, 2024 | From the USPTO record |
| US 8,703,186 | Abuse-resistant oral dosage forms and method of use thereof Term ended Ended no later than Apr 8, 2023 · From the USPTO record | Term ended | Ended no later than Apr 8, 2023 | From the USPTO record |
| US 6,620,439 | Chrono delivery formulations and method of use thereof Term ended Term ended Oct 3, 2020 · From the USPTO record | Term ended | Term ended Oct 3, 2020 | From the USPTO record |
| US 6,926,909 | Chrono delivery formulations and method of use thereof Term ended Ended no later than Oct 3, 2020 · From the USPTO record | Term ended | Ended no later than Oct 3, 2020 | From the USPTO record |
| US 6,984,402 | Chrono delivery formulations and method of treating atrial fibrillation Lapsed on the fee record Ended Jan 10, 2014 · From the USPTO record | Lapsed on the fee record | Ended Jan 10, 2014 | From the USPTO record |
| US 5,871,776 | Controlled-release nifedipine Term ended Term ended no later than Feb 16, 2019 · Low confidence | Term ended | Term ended no later than Feb 16, 2019 | Low confidence |
| US 5,902,632 | Method of preparation of controlled release nifedipine formulations Term ended Term ended no later than May 11, 2019 · Low confidence | Term ended | Term ended no later than May 11, 2019 | Low confidence |